MedTrace Logo

Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer

NCT02615223 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2017-06-12

No results posted yet for this study

Summary

This trial is going to evaluate tumor control and quality of life in patients with prostate cancer treated with endocrine therapy with or without cryoablation.

Conditions

  • Stage IV Prostate Cancer

Interventions

PROCEDURE

cryoablation

Cryoablation therapy

DRUG

Bicalutamide

bicalutamide

DRUG

luteinizing-hormone releasing-hormone (LHRH) agonist

luteinizing-hormone releasing-hormone (LHRH) agonist

Sponsors & Collaborators

  • Peking University First Hospital

    collaborator OTHER

  • Tianjin First Central Hospital

    collaborator OTHER

  • Shandong Cancer Hospital and Institute

    collaborator OTHER

  • Shanghai Jiao Tong University School of Medicine

    collaborator OTHER

  • The Third Xiangya Hospital of Central South University

    collaborator OTHER

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    collaborator OTHER

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    collaborator OTHER

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    collaborator OTHER

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Principal Investigators

  • Zhi Guo · Tianjin Medical University Cancer Institue and Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2017-12-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02615223 on ClinicalTrials.gov